Frequency and characteristics of the most commonly used VH genes in MCL compared with normal CD5+ IgM+ B cells and CLL
. | V1-08 . | V3-21 . | V3-23 . | V4-34 . | V4-59 . |
|---|---|---|---|---|---|
| Frequency in CD5+ B cells, %* | — | — | 13.9 | 3.5 | 6.3 |
| No. VH mutated | — | — | 9 of 20 | 0 of 5 | 0 of 9 |
| Frequency in CLL, %† | 1 | 4.7 | 4.7 | 7.8 | 2.1 |
| No. VH mutated | 0 of 3 | 8 of 14 | 8 of 14 | 19 of 23 | 3 of 8 |
| Frequency in MCL, % | 10.1 | 12.1 | 7.4 | 15.5 | 6.8 |
| No. VH mutated | 3 of 5 | 0 of 18 | 7 of 11 | 2 of 23 | 9 of 10 |
| Median CDR3 length, codons | 13 | 18 | 16 | 14 | 10 |
| Frequent D segment | — | D3-3: 5 of 15 | — | — | — |
| Frequent JH | JH4b: 6 of 15;JH5b: 6 of 15 | JH6: 12 of 17 | — | JH5b: 9 of 23;JH4b: 9 of 23 | JH4b: 7 of 10 |
| Frequent genomic aberration | +3q: 10 of 14 | — | — | — | 6q-: 4 of 6 |
| Patients with CR | 2 of 7 | 3 of 10 | 1 of 7 | 4 of 20 | 5 of 8 |
| Median OS, mo (no. patients) | 43.3 (8) | 103.4 (12) | 33.4 (8) | 34.5 (21) | 45.1 (9) |
. | V1-08 . | V3-21 . | V3-23 . | V4-34 . | V4-59 . |
|---|---|---|---|---|---|
| Frequency in CD5+ B cells, %* | — | — | 13.9 | 3.5 | 6.3 |
| No. VH mutated | — | — | 9 of 20 | 0 of 5 | 0 of 9 |
| Frequency in CLL, %† | 1 | 4.7 | 4.7 | 7.8 | 2.1 |
| No. VH mutated | 0 of 3 | 8 of 14 | 8 of 14 | 19 of 23 | 3 of 8 |
| Frequency in MCL, % | 10.1 | 12.1 | 7.4 | 15.5 | 6.8 |
| No. VH mutated | 3 of 5 | 0 of 18 | 7 of 11 | 2 of 23 | 9 of 10 |
| Median CDR3 length, codons | 13 | 18 | 16 | 14 | 10 |
| Frequent D segment | — | D3-3: 5 of 15 | — | — | — |
| Frequent JH | JH4b: 6 of 15;JH5b: 6 of 15 | JH6: 12 of 17 | — | JH5b: 9 of 23;JH4b: 9 of 23 | JH4b: 7 of 10 |
| Frequent genomic aberration | +3q: 10 of 14 | — | — | — | 6q-: 4 of 6 |
| Patients with CR | 2 of 7 | 3 of 10 | 1 of 7 | 4 of 20 | 5 of 8 |
| Median OS, mo (no. patients) | 43.3 (8) | 103.4 (12) | 33.4 (8) | 34.5 (21) | 45.1 (9) |
Features with strong associations in MCL are shown in bold letters. — indicates no frequent D, JH, or genomic aberration was assignable.
VH gene use in CD5+/IgM+ B cells from healthy donors according to Brezinschek et al45 ; the frequency of V1-08 and V3-21 was not reported.
VH gene use in CLL, as reported by Kröber et al.46